Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Antithrombotic efficacy of MAb-LE2E9 shown in a murine model of venous thrombosis

Aug. 21, 2002

Intimatan superior to dalteparin in canine model of vessel wall injury thrombosis

Aug. 14, 2002

ConjuChem terminates DAC:TI development

Aug. 13, 2002

Novel thrombin inhibitors in Merck & Co. pipeline

Aug. 12, 2002

Inspire and Discovery collaborate on P2Y12 antagonist program for cardiovascular disease

Aug. 9, 2002

Factor Xa/factor VIIa inhibitors reported by Aventis

Aug. 8, 2002

New factor Xa/factor VIIa inhibitors in early development at Merck

Aug. 5, 2002

Potential new therapeutic agent for arterial thrombosis discovered in Taiwan

Aug. 5, 2002

Novel antithrombin agents prepared and tested at Servier

Aug. 2, 2002

Bivalirudin + abciximab for percutaneous coronary revascularization

Aug. 2, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...